Drugmakers turn focus to fatty liver, hepatitis B treatments
The drugs on clinical trial, once approved, could reach annual sales of as much as US$10b, say industry analysts
Add BT as a preferred source
New York
NOW that new medicines promise to cure millions of hepatitis C patients in coming years, drugmakers including Gilead Sciences Inc are turning their attention to other liver diseases, with a potential market that could rival the success of statins, which generated more than US$30 billion a year in sales at their peak.
Several companies are working on treatments for hepatitis B, which can be controlled but not yet cured, and for fatty liver conditions caused by rising obesity, which without treatment could affect half of all Americans by 2030, according to the American Liver Foundation (ALF). Some of the drugs will address advanced fibrosis and cirrhosis, which are the scarring that virtually all liver diseases cause without effective treatments. Each of these drugs, once approved, could reach annual sales of as much as US$10 billion, industry analysts said.
Copyright SPH Media. All rights reserved.
